KAMADA » INVESTORS

INVESTMENT HIGHLIGHTS

  • Rapidly Growing, Globally Positioned Biopharmaceutical Company
    - Focused on Orphan Diseases and Plasma Derived Protein Therapeutics
     
  • Flagship Product Glassia® Approved for Alpha-1 Antitrypsin Deficiency Disorder
    - Has a Unique and Differentiated Product Profile and Represents an Exciting Growth Opportunity
     
  • Significant Opportunity in Novel Inhaled AAT Undergoing Pivotal Clinical Development
     
  • Validating Strategic Partnerships with Industry Leaders Baxter, Chiesi, Kedrion and Pari Pharma
     
  • Valuable R&D Pipeline Focused on Various Orphan Indications
     
  • Integrated, Efficient and Scalable Best-in-class Patented Platform Technology and Know-How
     
  • Strong Financial Profile with Increasing Profitability

LATEST NEWS

Glassia (more than) half full: "Bioworld Today" features Kamada as its top-story

Mar. 20, 2017

This week's top- story is about Kamada's GVHD clinical program and other interesting clinical implications of its AAT pipeline.

Kamada to Host R&D Day Focused on Graft versus Host Disease (GvHD)

Mar. 3, 2017

The company will host a Research and Development Day to highlight Graft versus Host Disease (GvHD) in New York City on March 3 from 12:00pm to 1:30pm Eastern Time.

More News

FINANCIAL REPORTS

Annual Report 2016

Dec. 31, 2016

Q3 / 2016 Financial Report

Nov. 10, 2016

Q2 / 2016 Financial Report

Aug. 3, 2016

More Reports

STOCK QUOTE

NASDAQ

KMDA:$7.2
Change:0.00%
Date & Time:4/27/2017 2:43pm
For more information: KAMADA on NASDAQ website

TASE

Share price                                             Daily volume(NIS)                

Click here for more information 

 Convertible bond                                  Daily volume(NIS)

Click here for more information

 For more information: KAMADA on Tel- Aviv Stock Exchange website

CORPORATE GOVERNANCE

Please click "Read more" to view Kamada's Corporate Governance items.

Read more

IR CONTACT & FAQ

Gil Efron
CFO
ir@kamada.com

Bob Yedid
LifeSci Advisors
646-597-6989
bob@lifesciadvisors.com

 

Read more